We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Dietary Pill Could Reduce Fat and Sugar in Food

By LabMedica International staff writers
Posted on 07 Jun 2011
Print article
A new nanocomplex dietary supplement that can be taken before meals could substantially reduce the amount of fat and sugar absorbed.

Researchers at Hebrew University (Jerusalem, Israel) and Harvard University (Boston, MA, USA) developed the nanocomplex based on naringenin, a flavonoid aglycone responsible for the bitter taste in grapefruit, which is poorly absorbed by the body when in its natural form. To overcome this problem, the solubility of naringenin was enhanced by complexation with Hydroxypropoyl-β-cyclodextrin (HPβCD), which increased the solubility of naringenin by over 400-fold, and its transport across a model of the gut epithelium by 11-fold. As an added benefit, when the molecule is turned into cyclodextrin, it becomes sweet; thus, naringenin is no longer bitter.

The researchers then tested the product on rats, and found that the nanocomplex increased naringenin plasma concentrations values by 7.4-fold. Moreover, when the complex was administered just prior to a meal, it decreased very low-density lipoprotein (VLDL) levels by 42% and increased the rate of glucose clearance by 64%, compared to naringenin alone. Histology and blood chemistry analysis indicated this route of administration was not associated with damage to the intestine, kidney, or liver. According to the researchers, these results suggest that the complexation of naringenin with HPβCD is a viable option for the oral delivery of naringenin as a therapeutic entity with applications in the treatment of dyslipidemia, diabetes, and hepatitis c virus (HCV) infection. The study was published in the April 6, 2011, issue of PLoS One.

"The complex is special in that it is taken just before a meal as a preventative measure," said lead author Yaakov Nahmias, PhD, of the Hebrew University School of Engineering and Computer Science. "In comparison, existing medications are given only after chronic development of abnormal lipid levels in the blood."

Related Links:
Hebrew University
Harvard University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.